351
Ñïèñîê ëèòåðàòóðû
Group // Ann Oncol. – 2010. – Vol. 21 (Suppl 5). – P.
v257-260.
65. Lee SK., Dawson J., Lee JA., Osman G., Levitin MO.,
et al. Management of cancer pain: 1. Wider implications
of orthodox analgesics. International Journal of General
Medicine 2014:7 49–58
66. Mercadante S., Porzio G., Gebbia V. New opioids. J Clin
Oncol. 2014 Jun 1;32(16):1671-6
67. Moss J, Rosow CE. Development of peripheral opioid
antagonists: new insights into opioid effects. Mayo Clin
Proc. 2008;83:1116-1130.
68. Pharmacologic Treatment of Cancer-related Fatigue /
J.K. Carroll [et al.] // The Oncologist. – 2007. – Vol.12
(Suppl.1). – P.43 – 51.
69. Pharmacology of pain / P. Beaulieu [et al.]. – Seattle, WA:
IASP Press, 2010. – 622 p.
70. Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to
resist/deter abuse. Drugs 2010;70(13):1657–1675
71. Smith H.S. Combination Opioid Analgesics. Pain Physician
2008; 11:201-214.
72. Use of Opioid Analgesics in the Treatment of Cancer Pain:
Evidence-based Recommendations from the EAPC //
Lancet Oncol. – 2012. – Vol. 13. – P. e58-e68.
73. Webster L. Update on abuse-resistant and abuse-
deterrent approaches to opioid formulations. Pain Med
2009;10(S2):S124–S133.
74. White Paper on standards and norms for hospice and
palliative care in Europe: part 1 and 2. Recommendations
from the European Association for Palliative Care, 2010.
Available from: URL:
aspx?fileticket=z4a-8JkAnFo%3d&tabid=732.
